Cardiol Therapeutics Class Stock Performance
| CRDL Stock | CAD 2.26 0.05 2.16% |
The firm shows a Beta (market volatility) of 1.26, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cardiol Therapeutics will likely underperform. At this point, Cardiol Therapeutics has a negative expected return of -0.13%. Please make sure to confirm Cardiol Therapeutics' treynor ratio, value at risk, skewness, as well as the relationship between the maximum drawdown and potential upside , to decide if Cardiol Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cardiol Therapeutics Class has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
1 | Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares CRDL Stock News - StockTitan | 10/09/2024 |
2 | Cardiol Therapeutics Faces Rising Losses and Falling Assets - TipRanks | 11/14/2024 |
3 | Cardiol Therapeutics Shares Up 1.8 percent - Whats Next - MarketBeat | 11/22/2024 |
| Begin Period Cash Flow | 59.4 M |
Cardiol |
Cardiol Therapeutics Relative Risk vs. Return Landscape
If you would invest 258.00 in Cardiol Therapeutics Class on September 3, 2024 and sell it today you would lose (32.00) from holding Cardiol Therapeutics Class or give up 12.4% of portfolio value over 90 days. Cardiol Therapeutics Class is generating negative expected returns and assumes 3.896% volatility on return distribution over the 90 days horizon. Simply put, 34% of stocks are less volatile than Cardiol, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Cardiol Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cardiol Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cardiol Therapeutics Class, and traders can use it to determine the average amount a Cardiol Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.034
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CRDL |
Estimated Market Risk
| 3.9 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.13 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cardiol Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cardiol Therapeutics by adding Cardiol Therapeutics to a well-diversified portfolio.
Cardiol Therapeutics Fundamentals Growth
Cardiol Stock prices reflect investors' perceptions of the future prospects and financial health of Cardiol Therapeutics, and Cardiol Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cardiol Stock performance.
| Return On Equity | -1.08 | |||
| Return On Asset | -0.54 | |||
| Current Valuation | 168.3 M | |||
| Shares Outstanding | 81.6 M | |||
| Price To Book | 17.64 X | |||
| Price To Sales | 1,274 X | |||
| EBITDA | (29.54 M) | |||
| Cash And Equivalents | 59.47 M | |||
| Cash Per Share | 0.48 X | |||
| Total Debt | 174.34 K | |||
| Debt To Equity | 1.00 % | |||
| Book Value Per Share | 0.43 X | |||
| Cash Flow From Operations | (25.18 M) | |||
| Earnings Per Share | (0.54) X | |||
| Total Asset | 36.7 M | |||
| Retained Earnings | (142.58 M) | |||
About Cardiol Therapeutics Performance
By examining Cardiol Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Cardiol Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Cardiol Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Cardiol Therapeutics Inc., a biotechnology company, engages in the research and commercial development of proprietary drug formulations for the treatment of heart failure and cancer. The company was incorporated in 2017 and is headquartered in Oakville, Canada. CARDIOL THERAPEUTICS operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. It employs 6 people.Things to note about Cardiol Therapeutics performance evaluation
Checking the ongoing alerts about Cardiol Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cardiol Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cardiol Therapeutics generated a negative expected return over the last 90 days | |
| Cardiol Therapeutics has high historical volatility and very poor performance | |
| Cardiol Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (28.13 M) with profit before overhead, payroll, taxes, and interest of 78.76 K. | |
| Cardiol Therapeutics Class has accumulated about 59.47 M in cash with (25.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.48. | |
| Latest headline from news.google.com: Cardiol Therapeutics Shares Up 1.8 percent - Whats Next - MarketBeat |
- Analyzing Cardiol Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cardiol Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Cardiol Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cardiol Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cardiol Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cardiol Therapeutics' stock. These opinions can provide insight into Cardiol Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.